NextSeq 2000 Validation of NGeneBio’s Oncology Panels

As NGS technology advances, validating sequencing platforms is crucial for clinical accuracy. NGeneBio’s oncology panels BRCAaccuTest™ PLUS, HEMEaccuTest™ DNA, and ONCOaccuPanel™ DNA were successfully tested on NextSeq 2000, showing high concordance with MiSeq and NextSeq 550.

Key points:

🔹 Enhanced efficiency: Sequence multiple panels in a single run
🔹 High accuracy: Consistent variant detection across platforms
🔹 Scalable and cost-effective: Maximized throughput without compromising quality

📥 Download the white paper now!